The Summary
A massive UK study involving over 165,000 dementia patients uncovered that risperidone, a widely used antipsychotic for severe agitation, significantly elevates stroke risk. Crucially, this risk extends to all dementia patients, including those with no history of heart disease or stroke, contradicting prior assumptions. As the only drug of its kind licensed for dementia, these findings have major implications for its use as a last-resort treatment.
Why this is interesting
This research is vital for anyone caring for or living with dementia, particularly if risperidone is being considered or currently prescribed. It prompts important conversations with healthcare providers about the risks versus benefits of this medication. Understanding these findings empowers families to advocate for safer treatment plans, ensuring all available options are thoroughly evaluated to minimize stroke risk and improve patient safety.